PFIZER’S CTI AND CCFA REQUEST PROPOSALS FOR
BIOOTHERAPEUTIC AND SMALL-MOLECULE TARGETS

Pre-Proposal Deadline: October 7, 2016

Pfizer’s Centers for Therapeutic Innovation (CTI) and the Crohn’s and Colitis Foundation of America (CCFA) are joining forces to support the translation of promising Crohn’s disease and ulcerative colitis research. The goal of the collaboration is to identify new compounds with the potential to accelerate drug development.

What We Look For

- **Strong project rationale**, demonstrated association between target biology and disease mechanism
- **Novel drug targets** with potential to lead to differentiated drugs
- **Link between target pathway and human disease**
- **Ability to address unmet medical needs**
- **Feasibility**: tractable target, discovery/development plan

Modalities

- **Large Molecules** (antibodies, proteins, peptides, ADCs, Fusions) or **Small Molecules** (target classes include kinases, GPCRs, ion channels, transporters, serine hydrolases, and epigenetic targets)

Therapeutic Areas of Interest

- **Inflammation and Immune disorders**: Crohn’s disease and ulcerative colitis

Pre-proposal Submission Process

Submission entails a brief, non-confidential 2-3 page overview of the target, mechanism (including evidence for disease linkage), and the proposed therapeutic drug. At a high level, the pre-proposal should suggest how the therapeutic hypothesis could be tested in the clinic.

For More Information

Please contact Mary Faris (mary.faris@pfizer.com), and Andres Hurtado-Lorenzo (ahurtadolorenzo@ccfa.org)

Advantages to Collaborating with Us

A partnership with CTI and CCFA may include collaborative use of Pfizer’s technologies, publishing rights, and financial awards in the form of milestone and royalty payments for successful programs, in addition to providing appropriate funds for carrying out the collaborative work.

All researchers and clinicians whose work meets these criteria are invited to apply. **Please submit pre-proposals to your Technology Transfer Office by October 7, 2016.**